Open AccessEffect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer
Author(s) -
FengMing Kong,
Randall K. Ten Haken,
Matthew J. Schipper,
Kirk A. Frey,
James A. Hayman,
Milton D. Gross,
Nithya Ramnath,
Khaled A. Hassan,
M.M. Matuszak,
Timothy A. Ritter,
Nan Bi,
Weili Wang,
Mark B. Orringer,
Kemp B. Cease,
Theodore S. Lawrence,
Gregory P. Kalemkerian
Publication year - 2017
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2017.0982
Subject(s) - medicine , carboplatin , lung cancer , nuclear medicine , positron emission tomography , radiation therapy , performance status , cancer , chemotherapy , radiology , oncology , cisplatin
Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabolic shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment provides an opportunity to deliver higher-dose radiation to the more aggressive areas of the tumor to improve local tumor control without increasing RT-induced lung toxicity (RILT), and possibly improve survival.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom